Nurr1:RXR activating compounds for simultaneous treatment of symptoms and pathology of Parkinson's disease

A compound of formula (I)

• or a pharmaceutically acceptable salt thereof, wherein n is 0 to 2, p is 0 to 2, X is N(R6);
• Cy is a phenyl ring or a heteroaromatic 6-membered ring containing between 1 and 4 heteroatoms;
• each R1 is independently selected from the group consisting of halogen, cyanate, isocyanate, thiocyanate, isothiocyanate, selenocyanate, isoselenocyanate, alkoxy, trifluoromethoxy, azido, cyano, nitro, hydroxy, acyl, mercapto, carboxyl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —OR7, —SR7, and —N(R8)R7;
• each R2 is independently selected from the group consisting of halogen, cyanate, isocyanate, thiocyanate, isothiocyanate, selenocyanate, isoselenocyanate, alkoxy, trifluoromethoxy, azido, cyano, nitro, hydroxy, acyl, mercapto, carboxyl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —OR7, —SR7, and —N(R8)R7;
• R3 is selected from the group consisting of halogen, cyanate, isocyanate, thiocyanate, isothiocyanate, selenocyanate, isoselenocyanate, alkoxy, trifluoromethoxy, azido, cyano, nitro, hydroxy, acyl, mercapto, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, OR7, —SR7, —N(R8)R7, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl and optionally substituted heterocyclyl;
• R4 is a haloalkyl;
• R5 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted aryl;
• R6 is selected from the group consisting of hydrogen and optionally substituted alkyl;
• each R7 is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, optionally substituted aryl-alkyl, and optionally substituted heterocyclyl;
• and
• each R8 is independently selected from the group consisting of hydrogen and optionally substituted alkyl;
• and wherein the compound is not a compound selected from the group consisting of:
• i. ethyl 4-(5-allyl-6-methyl-2-phenylpyrimidin-4-ylamino)benzoate;
• ii. methyl 4-(5-allyl-6-methyl-2-phenylpyrimidin-4-ylamino)benzoate;
• iii. 4-(6-methyl-2-phenyl-5-propylpyrimidin-4-ylamino)benzoic acid;
• iv. 4-(5-isopropyl-6-methyl-2-phenylpyrimidin-4-ylamino)benzoic acid;
• v. 4-(5-ethyl-6-methyl-2-phenylpyrimidin-4-ylamino)benzoic acid;
• vi. 4-(2-(4-chlorophenyl)-5-ethyl-6-methylpyrimidin-4-ylamino)benzoic acid;
• vii. 4-(5-ethyl-6-methyl-2-phenylpyrimidin-4-yloxy)benzoic acid;
• viii. 4-(2-(4-chlorophenyl)-5-ethyl-6-methylpyrimidin-4-yloxy)benzoic acid;
• and
• ix. 4-(5-allyl-6-methyl-2-phenylpyrimidin-4-ylamino)benzoic acid.